Valion Bio advances Entolimod to U.S. government-funded efficacy study
VBIO•Valion Bio's Entolimod will enter a fully NIAID-funded therapeutic efficacy study at the Armed Forces Radiobiology Research Institute, with top-line results expected in early December.
1. Study to assess survival
The study will assess survival following radiation-induced gastrointestinal injury. NIAID will fully fund the study, and top-line results are expected in early December.
